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Introduction
Second Courses of TMS for Major 
Depressive Episodes 
Major depressive episodes (MDE) are 
painful, disabling and common. Remission is 
difficult to achieve (1) and relapse frequently 
occurs (2). Transcranial magnetic stimulation 
(TMS) is an effective treatment for acute MDE 
(3). However, the clinical gains from active 
treatment may be lost over time.  
Senova et al. (4) performed a meta-
analysis regarding the durability of the TMS-
induced response and found 52.9% lost response 
during the first six months post treatment. For 
comparison, Jelovac et al. (5) performed a meta-
analysis on ECT-induced remission and found 
37.7% relapsed during the first six months. 
However, the higher Senova et al. (4) figure 
refers to the loss of response, while the lower 
Jelovac et al. (5) figure refers to the greater 
change of relapse.  
There are reports of MDE patients who 
have experienced a beneficial outcome from 
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Abstract 
Background: Transcranial Magnetic Stimulation (TMS) is effective in major depressive 
episodes (MDE). However, MDE may follow a chronic, relapsing course, and some individuals may 
not satisfactorily respond to a first course of TMS.  
Objective: To investigate the outcome of second courses of TMS.
Method: A naturalistic investigation—we prospectively studied 30 MDE in-patients 
and routinely collected information, including pre- and post-treatment with Six-item Hamilton 
Depression Rating Scale (HAMD6), a six-item Visual Analogue Scale (VAS6) and the Clinical 
Global Impression-Severity (CGI-S). Two categories of patients were considered: i) those who had 
remitted with a first course, but relapsed, and ii) those who had not remitted with the first course. 
Results: Thirty individuals received a second TMS course. The mean time to the second 
course was 27.5 weeks. Based on the HAMD6, 26 (87%) achieved remission after the first course, 
and 22 (73%) achieved remission after the second course. Furthermore, based on the HAMD6 
results, of the four patients who did not achieve remission with a first course, three (75%) did so 
with a second course. 
Conclusion: In MDE, a second course of TMS is likely to help those who remitted to a first 
course and then relapsed, as well as those who did not achieve remission with a first course.
Keywords: transcranial magnetic stimulation, depression, neurostimulation
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TMS and then relapsed and received a further 
course. Dannon et al. (6) reported on four 
patients who had ‘completed a successful 
TMS course previously’ but had relapsed and 
received a second course—for three patients, 
the second courses were as ‘equally effective’ 
as the first; however, for the fourth patient, the 
second course was less beneficial. Fitzgerald 
et al. (7) reported the ‘real world’ responses of 
19 patients who had received from two to 
five TMS courses. In response to the second 
treatment course, using the Beck Depression 
Inventory (BDI), 12 patients achieved a > 50% 
reduction, five achieved a 25%–50% reduction 
and two did not change. Janicak et al. (8) 
followed 103 patients, and further TMS was 
prescribed for ‘symptom breakthrough’, which 
was defined as the loss of least one point on the 
Clinical Global Impression-Severity (CGI-S) 
for two weeks. They found 32 of the 36 patients 
(89%) benefited from the reintroduction of TMS. 
Philip et al. (9) studied medication-free 
patients over one year. The reintroduction of 
TMS was considered a success when the 17-item 
Hamilton Depression Rating Scale (HAMD17) 
score reached the total that had been achieved 
with the initial acute treatment—this occurred 
for 14 of 18 patients (78%) in one group and 
17 of 27 patients (63%) in another. Kelly 
et al. (10) found eight of 10 patients (80%) 
responded to a second course of TMS. Sackeim 
(11) concluded that reintroduction of TMS 
is unsuccessful in a ‘substantial proportion’ 
(approximately 30%) of cases.  
In clinical practice, second courses of 
TMS may also be provided when first courses 
have failed to achieve a favourable outcome 
(response or remission). Following such failure, 
it is common for patients to receive a range 
of other options, and with a continued lack of 
satisfaction, to return to TMS hoping for a better 
outcome with a second course. To the best of 
our knowledge, there is no published account 
examining the outcomes of second courses when 
a first course has been unsuccessful. 
We investigated the outcomes of a second 
course of TMS on the mood of patients with 
a history of MDE. Most of these patients had 
benefited from a first course; however, this 
benefit had been lost over time. There were also 
a few patients who had gained little from the first 
course but who came to a second course in hopes 
of a better outcome.   
Method
Participants
We provide TMS in a private hospital in a 
state capital in Australia. There is no government 
funding for TMS in Australia; consequently, 
in our region, patients (privately insured) are 
generally admitted to the hospital to receive 
TMS (this arrangement enables costs to be 
recouped). Our unit has an academic attachment, 
and the Melbourne Clinic Ethics Committee 
approved this study. TMS is provided at the 
request of the treating psychiatrist, provided 
the known contraindications can be excluded 
and the DSM-V MDE diagnostic criteria are 
satisfied. This was a naturalistic study, and it was 
prospective in that we set a goal of recruiting 30 
patients and accepted every patient who met the 
MDE inclusion criteria. A sample size of n = 30 
provided the ability to detect a small to medium 
effect size (f = 0.22; using G*Power programme 
version 3, with the power [1 – β] set at 0.80 
and α = 05, two-tailed), which was expected to 
be sufficient given the prior research findings 
regarding the medium to large effects of TMS 
(12). Patients remained under the care of their 
treating psychiatrist and continued to receive any 
prescribed medication. 
Procedure
The course included 20 daily TMS sessions 
over 22 days, with a two-day rest period after 10 
treatments. Stimulation was applied at the left 
dorsolateral prefrontal cortex at 110% MT, 10 Hz, 
4 s trains, 26 s inter-train interval and 75 trains 
(3000 pulses) per day. The prospective data 
collection commenced in January 2017 and was 
completed two years later.
Measures
Pre- and post-treatment, we routinely 
collected: i) the objective six-item Hamilton 
Depression Rating Scale (HAMD6) (13) as the 
primary outcome measure, ii) the objective 
Clinical Global Impression-Severity (CGI-S) (14) 
and 3) a subjective six-item visual analogue scale 
(VAS6) (15), which is designed to complement 
the HAMD6. Earlier, we had found the VAS6 was 
a valid measure of the core aspects of depression 
measured by the HAMD6 (16).
The VAS6 anchor points are placed at 
either end of 10 cm lines: No depression–Worst 
possible depression; Activities give normal 
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pleasure–Activities give no pleasure; No physical 
health concerns–Extreme physical health 
concerns; No feelings of guilt–Extreme feelings 
of guilt; Not anxious–Most anxious possible. 
The sixth HAMD6 item is an observational 
assessment of ‘retardation’ as a ‘best-fit’ match 
with the subjective anchor points we chose: 
No concentration problems–Most possible 
concentrations possible.  
Data Analysis
Repeated measures ANOVA was used to 
explore changes in the HAMD6, CGI-S and 
VAS6 over the four time points (pre-post the first 
treatment and pre-post the second treatment). 
Post-hoc t-tests were used to explore differences 
between pairs of scores—first course pre versus 
post, second course pre versus post, first course 
pre versus second pre and first course post versus 
second post. We used Bonferroni corrections 
of 0.0125 (0.05/4) as the significance level for 
post-hoc tests. Repeated measures ANCOVA was 
used in the same fashion, with the addition of the 
number of weeks between treatments used as a 
covariate.
We then explored the categories of 
remission and relapse on the HAMD6 and CGI-S 
by reporting the proportions of participants 
in each category. ‘Remission’ has been 
operationalised as an HAMD6 score of ≤ 4 (17) 
and a post-treatment CGI-S score of 2 or less 
(18). ‘Relapse’ is operationalised as a HAMD6 
score of > 7 (16). The HAMD6 score of > 4 to 7 is 
termed ‘partial remission’ (18). ‘Non-remission’ 
was operationalised as a CGI-S score > 2.
Results
Over the two-year period, we provided 
150 courses to 120 individuals with a mean age 
of 44.1 years (SD = 15.6, range 18–88 years), 
and the group included 25 males (21%). Thirty 
individuals (25% of the index cases), a group 
whose mean age was 48.0 (SD = 16.6; range 
20–76 years) and that included five males (17%), 
received a second course of TMS. The mean 
time between the first and second course was 
27.5 weeks (SD = 16.7, range 9–69 weeks). One 
third of the patients reported occasional mild, 
temporary headaches; there were no other side 
effects. 
Total scores were significantly reduced 
following each course across the HAMD6, CGI-S 
and VAS6 (Table 1). For the HAMD6, repeated 
measures ANOVA showed there was a significant 
main effect of time: f(3,87) = 141.5, P < 0.001, 
χ2 = 0.83. Post-hoc tests using paired samples 
t-tests showed a significant decrease in HAMD6 
total scores before and after each treatment 
(P < 0.001). There was no difference in HAMD6 
scores before the first and second course 
(P = 0.267) and no difference in first and second 
course post HAMD6 scores (P = 0.097). The 
number of weeks between the first and second 
course was used as a covariate to determine if 
it impacted the pre/post scores for the second 
course. The weeks had no impact: f(1,28) = 1.54, 
P < 0.23, χ2 = 0.05. 
We repeated the above for the CGI-S scores 
with similar findings: post scores had decreased 
significantly for each treatment course, and there 
was no difference between pre scores for the first 
course. The second course post score was higher 
than the first course post score: t(29) = -2.1, 
P = 0.043, which was not statistically significant 
based on the corrected significance level. The 
number of weeks between treatments had no 
impact. The VAS6 scores were similar to the 
above; the second course post score was higher 
than the first course post score: t(29) = -2.5, 
P = 0.017; however, this was not statistically 
significant based on the corrected significance 
level. 
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Table 1. Means and standard deviations for the pre-post scores (n = 30)
Time point
First course 
pre mean 
(SD)
First course 
post mean 
(SD)
Second 
course pre 
mean (SD)
Second 
course 
post mean 
(SD)
Significant differences
HAMD6 total 
score
11.1 (1.9) 3.0 (1.8) 10.4 (2.4) 3.8 (2.2) First course pre > post*
Second course pre > post*
CGI-severity 4.5 (0.6) 1.8 (0.7) 4.2 (0.7) 2.2 (0.8) First course pre > post*
Second course pre > post*
VAS total score 38.5 (7.9) 15.3 (9.5) 38.1 (8.0) 20.3 (9.3) First course pre > post*
Second course pre > post*
*P < 0.001
CGI-S Categories 
The CGI-S categories of remission and 
non-remission were also explored. For the first 
course, 100% were in non-remission before 
treatment and 27 (90%) moved into remission 
with treatment. For the second course, 100% 
were in non-remission before treatment and 20 
(67%) moved into remission with treatment.
HAMD6 Categories 
The HAMD6 categories of remission, partial 
remission and relapse were explored (Table 2). 
Before the first course, all 30 individuals were 
in relapse. After the first course, 26 (87%) were 
in remission, two (7%) in partial remission and 
two (7%) remained in relapse. The average weeks 
between the treatments was 26.2 (SD = 15.9) for 
those who achieved remission (n = 26) and 35.8 
(SD = 21.8) for those who did not (n = 4).
Before commencing the second course, 
29 (96%) individuals were in relapse, and one 
was in partial remission. After the second course, 
22 (73%) achieved a second remission, 3 (10%) 
were in partial remission and five (17%) were in 
relapse. 
Of the 26 individuals who had achieved 
remission following the first course of treatment, 
following the second course, 19 (73%) of them 
achieved remission, three achieved partial 
remission and four were in relapse. Of the two 
participants in partial remission following the 
first course, following the second course, one 
achieved remission and one remained in relapse. 
Of the two participants who had remained 
in relapse after the first course, following the 
second course, both achieved remission. Thus, 
three (75%) of those who had not achieved 
remission following the first course did so 
following the second. 
Table 2. Post treatment HAMD6 categories for first and second course of TMS
First course (post-treatment)
Remission Partial 
remission
Relapse Total
Second 
course (post-
treatment)
Remission 19 1 2 22
Partial 
remission
3 0 0 3
Relapse 4 1 0 5
Total 26 2 2 30
Of the 27 individuals who had achieved 
remission following the first course, following 
the second course, 17 (63%) achieved remission. 
Of the three who had not achieved remission 
following the first course, all three achieved 
remission following the second course (Table 3).  
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Table 3. Post treatment CGI-Severity categories for first and second courses of TMS
First course (post-treatment)
Remission Relapse Total
Second course (post-treatment) Remission 17 3 20
Relapse 10 0 10
Total 27 3 30
Discussion and Conclusion
This study aimed to understand the 
outcomes of a second course of acute TMS for 
MDE. 
Thirty individuals underwent a second 
course of TMS. Using our primary outcome 
measure (HAMD6), after their first course, 26 of 
the 30 (87%) achieved remission—of these 26, 
19 (73%) achieved remission after the second 
course. This suggests that certain feature/s of an 
individual and/or his/her disorder, separately 
or in concert, determine the likelihood of the 
individual-disorder combination responding to 
TMS and that such feature/s are relatively stable. 
However, not all patients responded to the 
first course. We also studied the clinical outcome 
to a second course of TMS supplied to four 
people who had not achieved full remission with 
a first course. These patients had already failed 
to respond to medication and psychotherapy; 
thus, they were patients with highly resistant 
depression. Three (75%) achieved a remission, 
while one did not change. Theoretically, this 
could suggest that certain feature/s of these 
individuals and/or their disorders had changed 
over the intervening period (an average of 36 
weeks), such that the second course produced 
the desired effect. Practically, this shows that 
a second course of TMS is worth further trials, 
even in severe cases that have not responded 
to an initial course. We do not know of this 
observation (that a second course may be 
successful when an initial course has failed) 
having been made previously in the literature; 
however, it is a known clinical practice.
The findings of a 73% remission rate 
following the second course of acute TMS was 
consistent with the findings of earlier authors. 
Sackeim (11) estimated that the re-introduction 
of TMS may produce remission in approximately 
70% of individuals. 
The limitations of this study include that 
it was neither placebo controlled nor blinded 
and that our patients continued to receive anti-
depressant medication and were hospitalised 
during treatment. Fitzgerald et al. (7) pointed 
out the difficulty of randomising and blinding 
studies when patients have experienced active 
treatment. All these patients were taking at least 
one anti-depressant, some were taking more 
than one anti-depressant and about half were 
also taking a mood stabiliser, anti-psychotic or 
benzodiazepine.  
Evidence suggests that about a third of 
those who achieve remission will need further 
treatment in the first post-treatment year (9, 
10, 20). Thus, relapse is a real-world event, and 
effective treatment options are needed.
The outcomes of second courses of TMS 
generally suggest the likelihood of a second 
remission. However, these studies have used a 
range of different tools and methods. Fitzgerald 
et al. (7) did not use formal criteria to define 
relapse, and Demirtas-Tatlidede et al. (21) 
considered response but not remission. Janicak 
et al. (8) did not measure subjective experience 
and employed a ‘symptom breakthrough’ 
defined using the CGI-S. Dunner et al. (20) 
reported the proportion of patients who received 
‘reintroduction’ TMS (36.2%); however, they 
did not provide specific details of the outcome. 
Philip et al. (9) provided second TMS courses 
of less than 20 treatments. Kelly et al. (10) did 
not use an objective measure and defined both 
response and remission using unconventional 
percentage reductions in BDI scores. These 
accounts of second TMS courses are generally 
components of larger studies that address many 
aspects of the treatment of MDD with TMS. We 
have approached the question prospectively, 
using standardised tools, with a view to further 
extending understanding. 
The mean weeks between the first and 
second treatment was 27.5 overall, 26 weeks 
for those who achieved remission after the first 
course (n = 26) and 36 weeks for those who did 
not (n = 4). There is a possible explanation for 
this longer period between treatments for those 
who did not achieve remission after the first 
www.mjms.usm.my 107
Original Article | Second courses of TMS for MDE
course: when patients achieved a good response 
to the first treatment, deterioration took place, 
and the treating psychiatrists were predisposed 
to arrange a further TMS course. However, when 
the initial treatment provided poor results, other 
things were presumably tried, and the patients 
came back only after unsuccessful trials of other 
potentially therapeutic agents.
We chose the visual analogue scale as our 
means of quantifying subjective experience 
because it is a long-established method that has 
been usefully applied in a range of fields, and 
it provides information about an experience 
the instant it is completed (rather than over 
recent days). A possible disadvantage of the 
VAS is that the unbroken continuum scoring 
system is unfamiliar to most subjects and may 
cause difficulties. We will consider a Likert 
scale for future studies. There was significant 
improvement in subjective symptoms; however, 
the first course post score was significantly lower 
than the second course post score (suggesting 
less subjective benefit from the second course). 
This may reflect reality. Another consideration 
is the unfamiliar continuum scoring method 
may have introduced possible inaccuracies. 
Furthermore, when suffering patients (who have 
been disappointed by multiple other treatments) 
experience a positive outcome to their first 
course of TMS, they are usually surprised and 
highly delighted—it is quite possible they develop 
unrealistic expectations for the second course. 
Nevertheless, consistent with objective scores, 
the subjective mood improved significantly with 
both first and second TMS courses.
We have demonstrated that for people 
who regularly relapse within a few weeks of 
achieving remission, scheduled short courses 
over a few days at monthly intervals may be 
useful in preventing complete relapse (12, 16). In 
the current study, we are considering a different 
group—the patients in the current study were 
less prone to extremely rapid relapse.
We found that of the four patients who 
did not respond to a first course of TMS, three 
responded to a second course. While these 
numbers are small, they show a second course 
(following a failed course) may be beneficial. 
Our plan is to systematically explore this 
phenomenon. 
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